Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Portola: Approval of AndexXa is a Major Positive (PTLA, Buy, $41.19)

Investment Opinion

Based on assumptions made in this report, I estimate that AndexXa could be valued by investors at $114 to…
Read more…

Portola: Management Guides to a Highly Probable US Launch of Bevyexxa in the December to February Timeframe (PTLA, Buy, $50.52)

Perspective on Stock Price Behavior

I began coverage of Portola with a Buy in a May 4, 2017 report at…
Read more…

Portola: September 4 Conference Call Provides Update on Potential Launch Date for Bevyxxa and Announces Price (PTLA, Buy, $57.29)

Investment Overview

Following approval of Bevyxxa, Portola stated that it expected to launch in the US in the September to November…
Read more…

Portola Pharmaceuticals: AndexXa BLA Resubmitted; Reiterating Buy (PTLA, $61.41, Buy)

Investment Thesis

Portola issued a press release on August 3, 2017 that reported it had just resubmitted the BLA for AndexXa,…
Read more…

Portola Pharmaceuticals:  Betrixaban Approval Triggers Big Stock Move-Now What Do We Do? (PTLA, Buy, $55.42)

Investment Thesis

There was considerable uncertainty as to whether the FDA would approve betrixaban so that the approval caused a sharp…
Read more…

Portola: Reiterating Buy Prior to June 24th PDUFA Date for Betrixaban (PTLA, Buy, $39.35)

Portola has two drugs in late stage development that I believe are likely to be approved in 2017 or early…
Read more…

Portola Pharmaceuticals: Initiating Coverage with a Buy (PTLA, $40.05)

 Overview of Report
I am initiating coverage of Portola Pharmaceuticals with a Buy and a 2021 price target of $426.This is…
Read more…